PE20040204A1 - Administracion de agentes para el tratamiento de la inflamacion - Google Patents
Administracion de agentes para el tratamiento de la inflamacionInfo
- Publication number
- PE20040204A1 PE20040204A1 PE2003000195A PE2003000195A PE20040204A1 PE 20040204 A1 PE20040204 A1 PE 20040204A1 PE 2003000195 A PE2003000195 A PE 2003000195A PE 2003000195 A PE2003000195 A PE 2003000195A PE 20040204 A1 PE20040204 A1 PE 20040204A1
- Authority
- PE
- Peru
- Prior art keywords
- integrin alpha
- disease
- treatment
- dimmer
- refers
- Prior art date
Links
- 206010061218 Inflammation Diseases 0.000 title abstract 3
- 230000004054 inflammatory process Effects 0.000 title abstract 3
- 102100032818 Integrin alpha-4 Human genes 0.000 abstract 3
- 108010041012 Integrin alpha4 Proteins 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000001575 pathological effect Effects 0.000 abstract 2
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 206010009887 colitis Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 229960005027 natalizumab Drugs 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UN METODO PARA REDUCIR DE MANERA CRONICA LA INFLAMACION PATOLOGICA QUE CONSISTE EN ADMINISTRAR UN AGENTE QUE INHIBE A LA INTEGRINA ALFA-4 O UN DIMERO QUE COMPRENDE INTEGRINA ALFA-4; MEDIANTE UNA INFUSION INTRAVENOSA EN LA CANTIDAD DE ALREDEDOR DE 1 MG/KG A 20 MG/KG DEL PACIENTE CADA CUATRO SEMANAS DURANTE UN PERIODO DE AL MENOS 6 MESES DE MANERA REPETIDA MANTENIENDO LA SATURACION DE RECEPTORES DE INTEGRINA EN AL MENOS ALREDEDOR DE 65 % A 100%, SIENDO EL AGENTE UN ANTICUERPO MONOCLONAL O UN FRAGMENTO DEL MISMO INMUNOLOGICAMENTE ACTIVO ES NATALIZUMAB Y EL DIMERO DE INTEGRINA ALFA-4 ES ALFA-4-BETA-1.TAMBIEN SE REFIERE A UNA COMPOSICION. SE PUEDE UTILIZAR PARA EL TRATAMIENTO DE INFLAMACION PATOLOGICA QUE ES CAUSADA POR ESCLEROSIS MULTIPLE, ENFERMEDAD INFLAMATORIA DEL TRACTO GASTRO INTESTINALTAL COMO ENFERMEDAD DE CROHN, COLITIS ULCEROSA O ENFERMEDAD INFLAMATORIA INTESTINAL
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37450102P | 2002-04-23 | 2002-04-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20040204A1 true PE20040204A1 (es) | 2004-04-08 |
Family
ID=38813807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003000195A PE20040204A1 (es) | 2002-04-23 | 2003-02-27 | Administracion de agentes para el tratamiento de la inflamacion |
Country Status (2)
| Country | Link |
|---|---|
| PE (1) | PE20040204A1 (es) |
| UY (1) | UY27688A1 (es) |
-
2003
- 2003-02-27 PE PE2003000195A patent/PE20040204A1/es not_active Application Discontinuation
- 2003-02-27 UY UY27688A patent/UY27688A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| UY27688A1 (es) | 2003-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022002592A1 (es) | Uso de agentes para el tratamiento de condiciones respiratorias | |
| CO5650245A2 (es) | Formulaciones dispersable de un agente anti-inflamatorio | |
| CO5611176A2 (es) | Administracion de agentes para el tratamiento de inflamacion | |
| HRP20230929T1 (hr) | Stabilni pripravci semaglutida i njihova upotreba | |
| PE20230819A1 (es) | Composiciones y usos de glp-1 | |
| NZ609719A (en) | Pharmaceutical composition | |
| EA200000468A1 (ru) | Терапевтическая композиция для введения толтеродина с контролируемым высвобождением | |
| AR049985A1 (es) | Tratamiento de combinacion para enfermedades malignas no hematologicas | |
| BRPI0506705A (pt) | composto de tiouréias azabenzofuran-substituìdas, composições farmacêuticas e seus usos | |
| DE60327843D1 (de) | Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid | |
| RU2014127298A (ru) | Применения иммуноконъюгатов, мишенью которых является cd138 | |
| EE200200107A (et) | Kiire algtoimega selektiivse serotoniini tagasihaaramise inhibiitori kasutamine ravimi valmistamiseks, mis on ette nähtud seksuaalse funktsioonihäireravimiseks | |
| EA200700214A1 (ru) | Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией | |
| EA201992759A1 (ru) | Ассоциация, включающая кислород и гиалуроновую кислоту, для местного вагинального применения | |
| ES2149733T1 (es) | Composicion farmaceutica oral con liberacion modificada que contiene 5-asa y metodo para el tratamiento de enfermedades intestinales. | |
| MX2025005378A (es) | Metodos para el tratamiento de enfermedades cardiovasculares | |
| Ch'en | Demonstration of macrofilaricidal action of Hetrazan, antimony and arsenic preparations in man | |
| AR068531A1 (es) | Dosis fija por inyeccion unica para ocrelizumab (2h7). uso de rituximab. formulacion farmaceutica. kit. | |
| AR069767A1 (es) | Tratamiento del melanoma con peptidos timosina alfa en combinacion con activador de apoptosis de choque termico entineoplastico (hsaa) | |
| AR048806A1 (es) | Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio | |
| PE20040204A1 (es) | Administracion de agentes para el tratamiento de la inflamacion | |
| Zweig et al. | Rectal administration of propylthiouracil in suppository form in patients with thyrotoxicosis and critical illness: case report and review of literature | |
| Winning et al. | Case report: nitazoxanide for treatment of refractory bony hydatid disease | |
| NO20055390L (no) | Thorium-227 for anvendelse i radioterapi pa mykvevssykdommer | |
| WO2024112527A3 (en) | Methods for the treatment of thyroid eye disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |